GH Research prices $150 million public offering with focus on developing mebufotenin therapies

From GlobeNewswire: 2025-02-04 20:52:00

GH Research PLC has priced its underwritten public offering in the US, offering 10,000,000 ordinary shares at $15.00 per share for total gross proceeds of $150 million. The offering is expected to close on February 6, 2025, with underwriters having a 30-day option to purchase an additional 1,500,000 shares. Cantor, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering. Interested investors can access the registration statement and prospectus related to the offering on the SEC’s website. GH Research PLC is focused on developing mebufotenin therapies for treatment-resistant depression.

Investors are advised on the completion of the proposed securities offering, subject to market conditions and other factors beyond GH Research PLC’s control. The company does not guarantee the consummation of the offering on the terms described. Forward-looking statements in the press release highlight uncertainties in predicting future results. Interested parties are encouraged to stay informed through GH Research PLC’s filings with the SEC. For investor relations, individuals can contact Julie Ryan at GH Research PLC via email at [email protected].



Read more at GlobeNewswire: GH Research Announces Pricing of $150 Million Public